{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:03:59Z","timestamp":1785168239926,"version":"3.55.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Primary aldosteronism (PA) is currently considered the most common cause of secondary and endocrine hypertension. Liquid chromatography-tandem mass spectrometry (LC-MS\/MS) as a new detection technique has been gradually applied in the diagnosis of PA. However, the diagnostic value of LC-MS\/MS methods for PA has not been systematically clinically validated. The aim was to access the diagnostic accuracy, sensitivity, and specificity of LC-MS\/MS methods as screening tools in PA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>A literature search of PubMed, Embase, Medline, Web of Science, Scopus, Science Direct, and Chinese databases was carried out to June 2022 with no language restriction. Data on sensitivity and specificity and other evaluation indicators were extracted and pooled with STATA and Meta-disc software. Heterogeneity was evaluated and meta-regression and subgroup analysis was performed to elucidate sources of heterogeneity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>12 studies of the diagnostic test were suitable and included in the meta-analysis. Pooled sensitivity, specificity, and diagnostic odds ratio were 0.89 (95% CI: 0.83-0.93), 0.87 (95% CI: 0.82-0.91), and 55 (95% CI: 28-110), respectively. Subgroup analysis assessed the diagnostic power of LC-MS\/MS based on the type of detection index. ARR and PAC based on LC-MS\/MS methods have the higher diagnostic value compared with other indices, diagnostic odds ratios were 121.65 (95% CI: 36.28-407.98) and 49.85 (95% CI: 24.87-99.93). There was considerable heterogeneity among studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>LC-MS\/MS methods had higher accuracy and reliability in the diagnosis of primary aldosteronism. LC-MS\/MS-based ARR and PAC can be further promoted and applied in the diagnosis of primary aldosteronism.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1032070","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T04:58:36Z","timestamp":1668747516000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical diagnostic value of liquid chromatography-tandem mass spectrometry method for primary aldosteronism in patients with hypertension: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Kai-Fang","family":"Hua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jama.253.4.558","article-title":"Landmark article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. By Jerome W. Conn, Edwin L. Cohen and David R. Rovner","volume":"253","author":"Conn","year":"1985","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0382-4","article-title":"Pathogenesis and treatment of primary aldosteronism","volume":"16","author":"Zennaro","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2010.169","article-title":"Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment","volume":"23","author":"Sechi","year":"2010","journal-title":"Am J Hypertens"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00121","article-title":"Long-term mortality for patients of primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis","volume":"11","author":"Meng","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00210-2","article-title":"Diagnosis and treatment of primary aldosteronism","volume":"9","author":"Reincke","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2021.03.005","article-title":"Primary aldosteronism","volume":"32","author":"Funder","year":"2022","journal-title":"Trends Cardiovasc Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.02.052","article-title":"Primary aldosteronism in patients in China with recently detected hypertension","volume":"75","author":"Xu","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2005.061184","article-title":"Plasma aldosterone assays: comparison between chemiluminescence-based and RIA methods","volume":"52","author":"Pizzolo","year":"2006","journal-title":"Clin Chem"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jsbmb.2016.05.014","article-title":"Endogenous glucocorticoid analysis by liquid chromatography-tandem mass spectrometry in routine clinical laboratories","volume":"162","author":"Hawley","year":"2016","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2008.116004","article-title":"Measurement of aldosterone in human plasma by semiautomated HPLC-tandem mass spectrometry","volume":"55","author":"Taylor","year":"2009","journal-title":"Clin Chem"},{"key":"B13","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.cca.2019.03.109","article-title":"Establishment of a rapid and simple liquid chromatography tandem mass spectrometry method for measuring aldosterone in urine","volume":"493","author":"Yin","year":"2019","journal-title":"Clinica Chimica Acta"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.03.015","article-title":"Combination of LC\u2013MS\/MS aldosterone and automated direct renin in screening for primary aldosteronism","volume":"433","author":"Juutilainen","year":"2014","journal-title":"Clinica Chimica Acta"},{"key":"B15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1507\/endocrj.EJ21-0278","article-title":"Comparison and commutability study between standardized liquid chromatography-mass spectrometry\/mass spectrometry (LC-MS\/MS) and chemiluminescent enzyme immunoassay for aldosterone measurement in blood","volume":"69","author":"Nishikawa","year":"2022","journal-title":"Endocrine J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0254-6450.2018.04.028","article-title":"[Risk on bias assessment: (6) a revised tool for the quality assessment on diagnostic accuracy studies (QUADAS-2)]","volume":"39","author":"Qu","year":"2018","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/os.12969","article-title":"Role of d-dimer and fibrinogen in the diagnosis of periprosthetic joint infection: A systematic review and meta-analysis","volume":"13","author":"Xu","year":"2021","journal-title":"Orthop Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2014.12.026","article-title":"The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis","volume":"21","author":"Hoeboer","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2017.09.012","article-title":"Diagnostic accuracy of ultrasound in patients with gout: A meta-analysis","volume":"47","author":"Lee","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12474","article-title":"Systematic reviews and meta-analyses of diagnostic test accuracy","volume":"20","author":"Leeflang","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13448","article-title":"MicroRNA-223 in gastrointestinal cancers: A systematic review and diagnostic meta-analysis","volume":"51","author":"Aalami","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.01.016","article-title":"The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed","volume":"58","author":"Deeks","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002510","article-title":"Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension","volume":"38","author":"Mulatero","year":"2020","journal-title":"J Hypertens"},{"key":"B27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1530\/EJE-20-0030","article-title":"Prospective evaluation of aldosterone LC-MS\/ MS-specific cutoffs for the saline infusion test","volume":"183","author":"Fries","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12831","article-title":"Diagnosis and treatment of primary aldosteronism: practical clinical perspectives","volume":"285","author":"Young","year":"2019","journal-title":"J Intern Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.cca.2012.10.026","article-title":"Implementation of liquid chromatography\/mass spectrometry into the clinical laboratory","volume":"420","author":"Wu","year":"2013","journal-title":"Clin Chim Acta"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001735","article-title":"Criteria for diagnosing primary aldosteronism on the basis of liquid chromatography-tandem mass spectrometry determinations of plasma aldosterone concentration","volume":"36","author":"Baron","year":"2018","journal-title":"J Hypertension"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-00527","article-title":"Aldosterone LC-MS\/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism","volume":"104","author":"Guo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1000-6699.2019.11.002","article-title":"Clinical significance of LC-MS\/MS aldosterone in screening for primary aldosteronism","volume":"35","author":"Lin","year":"2019","journal-title":"Chin J Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2015.01.003","article-title":"Laboratory challenges in primary aldosteronism screening and diagnosis","volume":"48","author":"Rehan","year":"2015","journal-title":"Clin Biochem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2022-0325","article-title":"Chinese Normotensive and essential hypertensive reference intervals for plasma aldosterone and renin activity by liquid chromatography-tandem mass spectrometry","volume":"60","author":"Cheng","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.05.002","article-title":"Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS\/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status","volume":"470","author":"Eisenhofer","year":"2017","journal-title":"Clinica Chimica Acta"},{"key":"B36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1515\/cclm-2019-0706","article-title":"Comparison of three different chemiluminescence assays and a rapid liquid chromatography tandem mass spectrometry method for measuring serum aldosterone","volume":"58","author":"Yin","year":"2019","journal-title":"Clin Chem Lab Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01041","article-title":"Aldosterone LC-MS\/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism","volume":"103","author":"Guo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1009-9158.2020.03.013","article-title":"Clinical utility value of urinary aldosterone detection by tandem mass spectrometry in primary hyperaldosteronism screening","volume":"43","author":"Ma","year":"2020","journal-title":"Chin J Lab Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000570660.50840.c1","article-title":"Primary aldosteronism: LC-MS\/MS assay for 24-hour urine aldosterone determination improves screening","volume":"37","author":"Travers","year":"2019","journal-title":"J Hypertension"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/1474515120944014","article-title":"Meta-analysis: How to quantify and explain heterogeneity","volume":"19","author":"Ruppar","year":"2020","journal-title":"Eur J Cardiovasc Nurs"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1032070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T04:58:40Z","timestamp":1668747520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1032070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":40,"alternative-id":["10.3389\/fendo.2022.1032070"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1032070","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]},"article-number":"1032070"}}